Autoreactive T cells directed against the cardiac muscle–specific antigen α-myosin underlie the heart inflammation experienced by some recipients of immune checkpoint inhibitors. The findings, from mouse models and a handful of patients, could help researchers develop strategies to prevent or treat the drug-related toxicity.

You do not currently have access to this content.